An injectable antibody that switches off a liver protein, producing one of the largest, most reliable drops in harmful cholesterol available. Added to standard treatment it lowers heart attacks, strokes, and artery-opening procedures and can shrink existing plaque. Safety looks clean, mostly minor injection-site effects. Its life-extending promise stays unproven; high cost limits access. (Full Review)

Protocol

Dose

140 mg every 2 weeks

Or 420 mg once monthly (given as three 140 mg injections); equivalent lowering

Timing

Any consistent time

No time-of-day requirement; maintaining the 2-week or monthly cadence is what matters

Backdrop

Add-on to a statin

Largest reductions when layered on maximally tolerated statin plus ezetimibe

Time to effect

Cholesterol drop

1–2 weeks

LDL falls substantially within one to two weeks; near-maximal after the first few doses

Event reduction

Months to years

Heart attack and stroke benefit accrues with sustained use and widens over time

Benefits

High: Dramatic LDL cholesterol and ApoB reduction; reduced risk of heart attack, stroke, and coronary revascularization

Medium: Lipoprotein(a) lowering; coronary plaque regression and stabilization; benefit in peripheral artery disease

Low: Cardiovascular and all-cause mortality reduction

Speculative: Lifespan extension through lifelong low ApoB; anti-inflammatory and other pleiotropic vascular effects

Contraindications

Serious hypersensitivity (anaphylaxis, angioedema) to evolocumab or excipients

Pregnancy and breastfeeding

Key Interactions

Redundant PCSK9-directed therapy (alirocumab, inclisiran)

Additive lipid-lowering agents (ezetimibe, bempedoic acid, inclisiran)

Additive lipid-lowering supplements (red yeast rice, plant sterols, soluble fiber, berberine, omega-3)

Risk & Side Effects

High: Injection-site reactions

Medium: Upper respiratory and flu-like symptoms

Low: Hypersensitivity and allergic reactions; neurocognitive effects

Speculative: Theoretical risks of very low LDL cholesterol; new-onset diabetes

Monitoring

Marker	Target	Why
LDL cholesterol	< 55 mg/dL (often < 30 achieved)	Primary target and main driver of plaque
ApoB	< 60–80 mg/dL	Counts actual atherogenic particle number
Lp(a)	< 75 nmol/L (≈ < 30 mg/dL)	Independent, inherited risk particle
hs-CRP	< 1.0 mg/L	Gauges residual vascular inflammation
Fasting glucose / HbA1c	70–85 mg/dL; HbA1c < 5.4%	Surveillance for the theoretical metabolic concern
ALT / AST	ALT < 25 (women) / < 30 (men) U/L	Safety check driven mainly by concurrent statin

Cadence: Baseline, then lipid/ApoB panel at 4–12 weeks after starting, then every 6–12 months; metabolic markers at least annually

Qualitative Assessment

Energy levels and exercise tolerance
Absence of injection-site problems or allergic symptoms
Cognitive clarity and memory
Overall adherence and comfort with the injection routine

Evolocumab for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment